Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. We did a systematic review of randomise... D Yahav,M Paul,A Fraser,... - 《Lancet Infectious Diseases》 被引量: 354发表: 2007年 Low plasma cefepime levels in critically ill sep...
Broad spectrum Gram-positive and Gram-negative organisms (building on Third Generation Cephalosporin coverage) Beta-Lactamase resistant organisms More AmpB beta lactamase resistant than second and Third Generation Cephalosporins Better activity against Citrobacter and Enterobacter Pseudomonas coverage (similar to...
Cefepime is a broad-spectrum fourth-generation cephalosporin with activity against both gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa. Cefepime is most commonly used for urinary tract infections, soft tissue infections, and febrile neutropenia. Cefepime does not work against inf...
Conclusion: Cefepime is an established and generally well tolerated parenteral drug with a broad spectrum of antibacterial activity which, when administered twice daily, provides coverage of most of the pathogens that may be causative in pneumonia. In randomized clinical trials in hospitalized patients ...
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved. cefepime (sĕf′ə-pēm′) n. A broad-spectrum cephalosporin antibiotic, C19H24N6O5S2, used in its hydrochloride form ...
It is essential to monitor every patient for signs of a hypersensitivity reaction, especially if they have previously reacted to other beta-lactams. In addition, since cefepime is often used empirically for broad-spectrum coverage, the culture sensitivities should have close monitoring to deescalate ...
As up to 80% of OXA-48-like positive isolates coproduce extended-spectrum β-lactamases, a combination of β-lactams with broad-spectrum β-lactamase inhibitors is required to counteract all OXA-48-producing strains effectively. Herein, we evaluated the activity of cefepime-taniborbactam against ...
This is of particular concern when considering problematic pathogens such as those producing extended-spectrum beta-lactamases, or P. aeruginosa and Acinetobacter spp., which may have high cefepime MICs (≥8 mg/l) and pose major therapeutic challenges, and if one takes into account that up to ...
This vulnerable group of patients often has indwelling catheters, which increase the risk of certain pathogens. A focus of infection may not be clear, supporting the use of a broad-spectrum regimen. As gram-positive bacteria are a leading cause of infections in febrile neutropenic patients, ...
Conclusion : Cefepime is an established and generally well tolerated parenteral drug with a broad spectrum of antibacterial activity which, when administered twice daily, provides coverage of most of the pathogens that may be causative in pneumonia. In randomized clinical trials in hospitalized patients...